Expression of p53 protein and the apoptotic regulatory molecules Bcl-2, Bcl-XL, and Bax in locally advanced squamous cell carcinoma of the lung

Lung Cancer

Volumn 45, Issue 2, 2004, Pages 181-188

  Shabnam, Mir Snober ^a   Srinivasan, Radhika ^b   Wali, Anjlina ^b   Majumdar, Siddhartha ^a   Joshi, Kusum ^b   Behera, Digambar ^b  

^a Postgrad Inst Medica1l Educ Res ^*  (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Apoptosis; Apoptotic index; Bax; Bcl 2; Bcl XL; Lung cancer; Squamous cell carcinoma

Indexed keywords

MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN P53;

ADVANCED CANCER; APOPTOSIS; ARTICLE; BRONCHOSCOPY; CANCER LOCALIZATION; CANCER STAGING; CHI SQUARE TEST; CLINICAL ARTICLE; CORRELATION ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG BIOPSY; LUNG SQUAMOUS CELL CARCINOMA; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WILCOXON SIGNED RANKS TEST;

ADULT; AGED; APOPTOSIS; BASE SEQUENCE; BCL-2-ASSOCIATED X PROTEIN; BIOPSY, NEEDLE; BRONCHOSCOPY; CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; INDIA; LUNG NEOPLASMS; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RISK ASSESSMENT; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 3042788475     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2004.01.021     Document Type: Article

References (32)

1. Boring C.C., Squires T.S., Tong T., Montgomery S. Cancer statistics, 1994. CA Cancer J Clin. 44:1994;7-26
2. Ihde D.C., Minna J.D. NSCLC. Part 1: biology, diagnosis and staging. Curr. Probl. Cancer. 15:1991;61-104
3. Korsmeyer S.J. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood. 80:1992;879-886
4. Symonds H., Krall L., Remington L., Seanz-Robles M., Lowe S., Jacks T. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 78:1994;703-711
5. Miyashita T., Reed J.C. Tumor suppressor p53 is a direct transcriptional regulator of the human Bax gene. Cell. 80:1995;293-299
6. Krajewski S., Tanaka S., Takayama S., Schibler M.J., Fenton W., Reed J.C. Investigation of the sub cellular distribution of the Bcl-2 oncoprotein: residence in the nuclear envelope. ER and outer mitochondrial membranes. Cancer Res. 53:1993;4701-4714
7. Borner C. Diminished cell proliferation associated with the death protective activity of Bcl-2. J. Biol. Chem. 271:1996;12695-12698
8. Kroemer G., Reed J.C. Mitochondrial control of cell death. Nat. Med. 6:2000;513-519
9. Antonsson B., Conti F., Ciavatta A., Montessuit S., Lewis S., Martinou L., et al. Inhibition of Bax channel-forming activity by Bcl-2. Science. 272:1997;370-372
10. L during apoptosis. Proc. Natl. Acad. Sci. U.S.A. 94:1997;3668-3670
11. Ito T., Deng X., Carr B., May W.S. Bcl-2 phosphorylation required for anti-apoptosis function. J. Biol. Chem. 277:1997;11671-11673
12. Ohsaki Y., Toyoshima E., Fujiuichi S., Matsui H., Hirata S., Miyokawa N., et al. Bcl-2 and p53 protein expression in non small cell lung cancers: correlation with survival time. Clin Cancer Res. 2:1996;915-920
13. Kim Y.-C., Park K.-O., Kern J.A., Park C.-S., Lim S.-C., Jang A.S., et al. The interactive effect of ras, HER2, p53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients. Lung Cancer. 22:1998;181-190
14. Cagini L., Monacelli M., Giustozzi G., Moggi L., Bellezza G., Sidoni A., et al. Biological prognostic factors for early stage completely resected non-small lung cancer. J. Surg. Oncol. 74:2000;53-60
15. Pastorino U., Andreola S., Tagliabue E., Pezzella F., Incarbone M., Sozzi G., et al. Immunocytochemical markers in stage I lung cancer: relevance to prognosis. J. Clin. Oncol. 15:1997;2858-2865
16. Brambilla E., Negoescu A., Gazzeri S., Lantuejoul S., Moro D., Brambilla C., et al. Apoptosis related factors p53, Bcl-2, Bax in neuroendocrine lung tumors. Am. J. Pathol. 149:1996;1941-1952
17. Behera D. Lung cancer in India: a perspective. Ind. J. Chest Dis. 8:1992;324-329
18. Bartel F., Meye A., Würl P., Kappler M., Bache M., Lautenschläger C., et al. Amplification of the MDM-2 gene, but not expression of splice variants of mdm-2 mRNA is associated with prognosis in soft tissue sarcoma. Int. J. Cancer. 95:2001;168-175
19. Anderson L., Seilhamer J. A comparison of selected mRNA and protein abundances in human liver. Electrophoresis. 18:1997;533-537
20. Zhang H., You seem S.A., Franklin W.A., Elder E., Landreneau R., Ferson P., et al. Differentiation and programmed cell death related intermediate biomarkers for the development of NSCLC; a pilot study. Hum Pathol. 29:1998;965-967
21. Hockenbery D.M., Zutter M., Hickey W., Nahm M., Korsmeyer S.J. Bcl-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc. Natl. Acad. Sci. U.S.A. 88:1991;6961-6965
22. Wei W., Yin X., Jin H. Study on expression of apoptosis related genes in non-small cell carcinoma. Zhonghua Jie He He Hu Xi Za Zhi. 22:1999;652-654
23. Brambilla E., Gazzeri S., Lantejoul S., Coll J.L., Moro D., Negoescu A., et al. p53 mutant immunophenotype and deregulation of p53 transcription pathway (Bcl-2, Bax, and Waf 1) in precursor bronchial lesions of lung cancer. Clin Cancer Res. 4:1998;1609-1618
24. Koty P.P., Zhang H., Levitt M.L. Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer. 23:1999;115-127
25. Koty P.P., Zhang H., Franklin W.A., Samuel A.Y., Landreneneau R., Levitt M.L. In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions. Lung Cancer. 35:2002;155-163
26. Vogel stein A., Kanzler K.W. p53 function and dysfunction. Cell. 70:1992;523-526
27. Lane D.P. p53 guardian of the genome. Nature. 358:1992;15-16
28. Tanaka F., Takata T., Yamada T., Yanagihara K., Otake Y., Miyahara R., et al. Apoptotic tumor cell death in response to cell proliferation is influenced by p53 status in resected non-small cell lung cancer. Lung Cancer. 36:2002;27-32
29. Borner M.M., Brousset P., Pfanner-Meyer B., Bacchi M., Vonlanthen S., Hotz M.A., et al. Expression of apoptosis regulatory proteins of the Bcl-2 family and p53 in primary resected non-small lung cancer. Br. J. Cancer. 79(5-6):1999;952-958
30. Jean mart M., Lantejoul S., Fievert F., Moro D., Sturm N., Brambilla C., et al. Value of immunohistochemical markers in preinvasive bronchial lesions in risk assessment of lung cancer. Clin Cancer Res. 9:2003;2195-2203
31. Galmarini M.C., Clarke L.M., Falette N., Puisieux A., Mackey J.R., Dumontet C. Expression of a non functional p53 affects the sensitivity of cancer cells to gemcitabine. Int. J. Cancer. 97:2002;439-445
32. Hanaoka T., Nakayama J., Haniuda M., Sato T.A. Immunohistochemical demonstration of apoptosis-regulated proteins. Int. J. Clin. Oncol. 7:2002;152-163